ClinicalTrials.gg
Not yet recruitingNCT05924906Updated Jul 3, 2023

A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of NB002 in Advanced Solid Tumor, sponsored by Suzhou Neologics Bioscience Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Suzhou Neologics Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a first-in-human, multicenter, open label, uncontrolled, non-randomized, phase 1a/1b study, to evaluate the safety, tolerability, and preliminary antitumor activity of NB002 in subjects with advanced solid tumors.

Read the detailed description

This study is a first-in-human, multicenter, open-label, uncontrolled, non-randomized, phase 1a/1b study. The study consists of a dose escalation part and a dose expansion part. In the escalation part, the primary objectives are to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) to establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or maximum administered dose (MAD) of NB002. The expansion part is to further evaluate the safety and tolerability of NB002 at the RDE dose established in the dose escalation part and to explore antitumor activity in the selected population. All subjects will be treated with NB002 via IV infusion at predefined dose levels Q3W on Day 1 of each 21-day Cycle.

The design of the dose escalation part will be provided below. Further details on dose expansion part will be updated later once more information on potentially benefiting tumor types is confirmed.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

This is the only study on the registry with Suzhou Neologics Bioscience Co., Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age at the time of signing .
  2. Diagnosis of histological or cytological confirmed locally advanced, recurrent and/or solid tumors that failed to respond to standard therapy, intolerant/ to currently available local therapies, or for whom no appropriate therapies are available (based on the judgement of the Investigator).
  3. Measurable or non- according to 1.1 in dose escalation stage and at least one measurable lesion is necessary for dose expansion stage.
  4. (ECOG) performance status (PS) of 0 or 1, and anticipated of ≥ 3 months.
  5. Adequate hematologic function based on the following (with no blood transfusion or hematopoietic stimulating factor therapy within 14 days prior to study drug administration):

    1. ≥1.2 ×10\^9/L
    2. count ≥75×10\^9/L
    3. ≥8.0 g/dL
  6. Adequate coagulation parameters based on the following:

    1. -International Normalized Ratio (PT-INR) ≤1.5× (upper limit of normal), unless coumarin derivatives are used.
    2. Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Subjects on anticoagulants may have coagulation parameters that exceed the criteria defined above.
  7. Adequate hepatic function based on the following:

    1. Total (TBIL) ≤1.5 × ULN and/or isolated elevations of indirect bilirubin are eligible for study participation.
    2. (ALT)/aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN for subjects with known hepatic metastases).
  8. Adequate renal function based on serum ≥30 mL/min (normal to moderate renal impairment) as determined by Cockcroft-Gault equation.
  9. A female patient is eligible to participate if she is not pregnant or breastfeeding, and

    • is not a or
    • A WOCBP must have a negative pregnancy test within 72 hours before the first dose of study drug administration, and additional pregnancy testing during and after study drug as defined in the SOA .
    • A WOCBP must consent to use highly effective methods or abstain from heterosexual activity from screening through 120 days following the last dose of study treatment.
  10. Fertile male subjects, defined as all males physiologically capable of conceiving offspring, with their WOCBP partner(s) must agree to use highly effective contraception. Sexually active males who have not had a vasectomy, and whose partner is reproductively capable, must agree to abstain from sexual intercourse or use barrier contraception from Screening through 120 days following the last dose of study treatment.
  11. Ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to first administration of study drug.
  2. Has had a known or suspected reaction to treatment with a mAb and/or the of NB002.
  3. Prior treatment with other TIM-3 inhibitors (e.g., mAbs).
  4. Prior palliative radiotherapy within 1 week of start of study treatment. Subjects must have recovered ( Grade ≤1) from all radiation-related toxicities.
  5. Any antitumor agent for the primary without delayed toxicity within 4 weeks or 5 half-lives, whichever is shorter, prior to first administration of study drug, except for Nitrosoureas and mitomycin C within 6 weeks prior to first administration of study drug and during study.
  6. Active , however, subjects who have undergone definitive radiation and/or surgery for the treatment of CNS metastases, who are stable by radiographic and clinical (neurological) assessment (performed within 4 weeks prior to first trial drug administration), and who are no longer taking pharmacologic doses of are eligible; subjects with or primary CNS malignancies (such as glioma, glioblastoma) are not eligible.
  7. Evidence of ileus on computed tomography (CT) scan.
  8. Patients with concurrent hematologic malignancies.
  9. Known active or prior infection with (HIV), or active infection with virus (HBV), or virus (HCV).
  10. Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks prior to first administration of study drug.
  11. Patients with an active, known or suspected disease, or a documented history of autoimmune disease or syndrome, requiring systemic steroids or other medications. procedure is allowed if all other inclusion/exclusion criteria are met.
  12. History of organ transplantation (e.g., stem cell or solid organ transplant)
  13. A significant pulmonary disease or condition.
  14. Patients with a current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.
  15. History of immune-related toxicity during prior treatment with an (ICI, e.g., PD-1/PD-L1 or CTLA-4 inhibitor), including any grade ≥3, and neurologic and/or ocular immune-related toxicity, pneumonitis, or cardiomyopathy of any grade that necessitated permanent discontinuation of that therapy. Patients with other Grade 1-2 immune-related toxicities on prior ICI therapy that have resolved are NOT excluded. Endocrine immune-related toxicities of grade \<3 are allowed, as long as they are controlled and/or asymptomatic. Substitution therapy following an immune-related endocrinopathy is allowed.
  16. Unresolved > Grade 1 toxicity associated with any prior antitumor therapy except for persistent Grade 2 alopecia, peripheral neuropathy, decreased , lymphopenia, hypomagnesemia, and/or end-organ failure being adequately managed by hormone replacement therapy:
  17. Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to first administration of study drug unless adequately treated and considered by the Investigator to be stable. Active uncontrolled bleeding or a known bleeding diathesis.
  18. Vaccination with (s) within 1 month prior to administration.
  19. Baseline corrected with Fridericia's method (QTcF) >470 ms (average of triplicate [ECG]).
  20. Unstable or severe uncontrolled medical condition (e.g., uncontrolled diabetes), psychiatric illness/social situations, or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the patient associated with his or her participation in the study.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    NB002 dose level 1

    NB002 is a recombinant humanized IgG1 monoclonal antibody

    Drug: NB002

  • Experimental
    NB002 dose level 2

    NB002 is a recombinant humanized IgG1 monoclonal antibody

    Drug: NB002

  • Experimental
    NB002 dose level 3

    NB002 is a recombinant humanized IgG1 monoclonal antibody

    Drug: NB002

  • Experimental
    NB002 dose level 4

    NB002 is a recombinant humanized IgG1 monoclonal antibody

    Drug: NB002

  • Experimental
    NB002 dose level 5

    NB002 is a recombinant humanized IgG1 monoclonal antibody

    Drug: NB002

  • Experimental
    NB002 dose level 6

    NB002 is a recombinant humanized IgG1 monoclonal antibody

    Drug: NB002

Interventions

  • DrugNB002

    Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AE), serious adverse events (SAE)

    AEs will be evaluated by the investigator, according to criteria outlined in the NCI CTCAE version 5.0

    Time frame: Up to 12 months

  2. Number of participants with dose-limiting toxicity (DLT), as defined in the protoocol

    All toxicities will be graded according to NCI CTCAE version 5.0 based on the investigator assessment. The DLT window of observation will be during Cycle 1 (21 days).

    Time frame: 21 days

Secondary outcomes

  1. Pharmacokinetics of NB002: Maximum plasma concentration of the study drug (Cmax)

    Maximum observed plasma or serum concentration.

    Time frame: Up to 12 months

  2. Pharmacokinetics of NB002: Time to maximum concentration (Tmax)

    Time to maximum concentration.

    Time frame: Up to 12 months

  3. Pharmacokinetics of NB002: Minimum plasma concentration of the study drug (Cmin)

    Minimum observed plasma or serum concentration over the dose interval.

    Time frame: Up to 12 months

  4. Pharmacokinetics of NB002: Area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration (AUC0-t)

    Area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t.

    Time frame: Up to 12 months

  5. Objective response (OR)

    Complete response (CR) or partial response (PR), as defined by RECIST v1.1

    Time frame: Up to 12 months

  6. Progression free survival (PFS)

    The time from first dose of study intervention until the date of objective disease progression or death

    Time frame: Up to 12 months

  7. Duration of response (DOR)

    The time from first response according to RECIST v1.1 until progression or death

    Time frame: Up to 12 months

  8. Pharmacodynamics (PD) activity (Level of binding of NB002 to TIM-3 )

    Receptor occupancy in peripheral blood mononuclear cells (PBMCs) or whole fresh blood

    Time frame: Up to approximately 3 months

  9. Immunogenicity of NB002

    The number and percentage of participants who develop detectable anti-drug antibodies (ADA).

    Time frame: Up to 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2023; primary completion for Apr 2026, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 29, 2023
StartEst.
Oct 2023
Primary completionEst.
Apr 2026
CompletionEst.
Jul 2026
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05924906
Lead sponsor
Suzhou Neologics Bioscience Co., Ltd.
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
Oct 2023 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jul 3, 2023

Study contacts

Alex Cheng
Contact
alex.cheng@neologicsbio.com
+86 135 2165 0955

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetylpyridinium

Start the discussion